Atea Pharmaceuticals director proposes 8,750-share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Atea Pharmaceuticals, Inc. (AVIR) director Bruce Polsky reported a proposed sale of 8,750 common shares, with an aggregate market value of $35,299.25 and an approximate sale date of November 19, 2026. The shares were acquired from the issuer on November 16, 2026, in an exercised-shares transaction paid for in cash. The notice also lists three sales during the past three months: 14,254 shares for gross proceeds of $60,840.35 on November 16; 8,720 shares for $35,155.55 on November 17; and 18,252 shares for $72,099.05 on November 18, 2026.
Key Figures
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.